Intracavernosal Injection Agents
Intracavernosal injection (ICI) is an effective option for erectile dysfunction, including when oral therapy is unsuitable or ineffective. AUA does not require every patient to fail oral drugs first: discuss the suitable options and preferences. EAU 2026 describes ICI as an alternative initial treatment for an informed patient or as a subsequent option. An in-office injection test and training should precede self-injection.[1][2]
Keep four uses distinct: vasoactive injections into the corpora for erections; diagnostic pharmacologic erection testing; intralesional plaque treatment for Peyronie's disease; and intracavernosal vasoconstrictor treatment to reverse a prolonged erection. Their drugs, sites and doses are not interchangeable.
Agents and formulations
| Agent / formulation | Role and mechanism | Regulatory / practical distinction |
|---|---|---|
| Alprostadil (PGE1): Caverject, Edex | Prostaglandin-mediated cAMP signaling relaxes cavernosal smooth muscle | FDA-approved ED injection products. Caverject also has a diagnostic-adjunct indication; follow the individual product's dosing and preparation instructions.[3][4] |
| Papaverine | Nonspecific phosphodiesterase inhibition | ED use is off-label; commonly combined with other agents. Priapism and fibrosis are important concerns.[2] |
| Phentolamine | Nonselective alpha-receptor blockade reduces sympathetic contraction | Off-label ED combination component. It can cause systemic hypotension/reflex tachycardia; it does not reliably prevent tachycardia from other agents.[2] |
| BiMix | Papaverine + phentolamine | Compounded; may avoid alprostadil-associated pain, but response and risk vary.[1][2] |
| TriMix | Alprostadil + papaverine + phentolamine | Compounded, with no single standard concentration. High response in clinical series is not proof that every mixture is superior or safer.[1][5] |
| QuadMix | TriMix + atropine | Less established salvage combination; do not interpret the extra drug as proven greater efficacy or safety.[1] |
| Aviptadil + phentolamine (Invicorp) | VIP-mediated cAMP activity plus alpha blockade | Used in the UK and selected other countries; local authorization and supply must be checked. It is not an FDA-approved US ED product.[2][6] |
The Caverject label states that the safety/efficacy of combining it with other intracavernosal vasoactive drugs has not been established and does not recommend such combinations. Specialist compounded TriMix practice is therefore distinct from labeled Caverject monotherapy.[3]
Alprostadil dosing: product-specific limits
| Product | Initial office dose: vasculogenic / psychogenic / mixed ED | Pure neurogenic ED, such as SCI | Upper labeled dose boundary |
|---|---|---|---|
| Caverject | 2.5 micrograms | 1.25 micrograms | Doses >60 micrograms not recommended |
| Edex | 2.5 micrograms | 1.25 micrograms | Studied dose range 1–40 micrograms; doses >40 micrograms not studied |
These starting categories are from the labels; do not automatically classify every post-pelvic-surgery patient as pure SCI-type neurogenic ED. Aim for the lowest effective dose producing an intercourse-suitable erection lasting no more than about one hour.[3][4]
Caverject and Edex have different office titration/redosing instructions. Use the actual product label, not a merged schedule. The patient remains under observation until detumescence. Once a home dose is established, use no more than three injections per week, separated by at least 24 hours; do not repeat a dose at home for an inadequate response or combine treatments without the prescriber's plan.[3][4]
For a compounded mixture, the prescription and teaching sheet must specify every concentration, the volume and the corresponding syringe marking. A number of syringe “units” does not identify a drug dose across different mixtures. Re-titration may be needed when formulation or concentration changes. Follow the dispensing pharmacy's product-specific storage and beyond-use instructions.[1]
Training and follow-up
Use the product's supplied or specified needle and preparation method. Caverject specifies a 29–30-gauge half-inch injection needle and dorsolateral injection in the proximal third of the penis. Avoid visible veins, the dorsal neurovascular structures and the ventral urethra; alternate sides/sites. Do not bend or reuse needles, and discard single-use material appropriately.[3][4]
Compress the injection site for five minutes or until bleeding stops. Anticoagulation increases local bleeding risk but is not a blanket reason to stop the anticoagulant; interruption requires a separate assessment of its indication and thrombotic risk. The Caverject label specifically advises compression for patients taking warfarin/heparin.[3]
Ensure the patient can demonstrate preparation, injection and sharps disposal, and has clear instructions for prolonged erection. Review tolerability, dose, penile examination and continued need; Caverject recommends reassessment approximately every three months. There is no universal 0.5-mL injection ceiling applicable to every labeled product and concentration.[3][4]
Contraindications and important adverse effects
The US Caverject label contraindicates use in men with hypersensitivity, penile implants or priapism-predisposing conditions such as sickle cell anemia/trait, leukemia or myeloma. It contraindicates ED treatment in penile fibrotic/anatomic conditions including Peyronie's disease, angulation and cavernosal fibrosis. Review the exact product and indication rather than assuming plaque injection and ED injection have identical restrictions.[3]
- Pain: alprostadil-associated penile pain is common and may affect adherence; adjustment or a different formulation can be considered.
- Fibrosis/curvature: inspect periodically and evaluate new plaques or angulation. Caverject treatment should be stopped if angulation or cavernosal fibrosis develops.
- Hypotension/bleeding: systemic exposure can be important; the Caverject label advises avoiding use with known cavernosal venous leakage. Cardiovascular fitness for sexual activity also matters.
- Prolonged erection: emergency instructions are essential. Caverject trials reported 4% erections lasting 4–6 hours and 0.4% lasting >6 hours, using historical study definitions. Those definitions do not mean it is safe to wait six hours.
Product-label safety details above apply to Caverject; compounded mixtures need their own assessment.[3]
Effectiveness and persistence with treatment
Coombs 2012 included 1,412 men with complete data from a tertiary program. Among TriMix users, 89% reported intercourse-capable erections; observed priapism was 0.5%. These are observational program results, not a randomized comparison establishing a universal 90% success rate. Response was lower in diabetic and irradiated patients, and discontinuation remained substantial.[5]
Al-Mitwalli 2025 reviewed 308 selected men switched to aviptadil/phentolamine after painful or ineffective alprostadil. At the three-month effectiveness assessment, 182/308 (59%) resumed penetrative activity; responses differed between pain-switchers and maximum-dose failures (76% versus 36%). One priapism event (0.3%) occurred. A single retrospective cohort cannot establish that this is the safest or best rescue formulation.[6]
Adherence depends on comfort, confidence, partner preferences, cost and recovery with other therapies. Offer early follow-up after teaching rather than assuming that a good office erection predicts durable home use.[1][5]
Diagnostic ICI and penile Doppler
Caverject's diagnostic label calls for an individual rigidity-producing dose using its vasculogenic/mixed titration framework, not a fixed 10–20-microgram starting dose for every patient. Specialist redosing protocols are distinct from home treatment instructions and require observation and a reversal plan.[3]
Incomplete relaxation, anxiety, dose response and measurement technique can affect Doppler interpretation. Redosing is a clinical decision, not an automatic command; reaching a maximum dose does not prove complete relaxation. For hemodynamic thresholds, technique and interpretive limitations, use the dedicated penile Doppler page.[2]
Prolonged erection and priapism rescue
Provide an explicit contact and emergency plan. An erection persisting four hours requires urgent assessment; concerning painful rigidity may warrant earlier contact. For a post-injection erection lasting 1–4 hours, the decision to intervene depends on rigidity, duration, drug/dose and patient factors. AUA/SMSNA identifies intracavernosal phenylephrine as the initial drug when treatment is needed; it does not require injection for every mild erection lasting under an hour.[7]
Established ischemic priapism requires prompt treatment with aspiration and intracavernosal phenylephrine, with or without irrigation. BP/heart-rate monitoring and careful preparation are essential. Use priapism management for dosing and escalation, rather than duplicating a rescue recipe here.[7]
Peyronie's plaque injections
Collagenase and other intralesional agents are injected into a plaque, not prescribed as cavernosal erection drugs. See Peyronie's disease agents for selection, modeling, dosing and rupture precautions. Evidence from intralesional verapamil cannot be inferred from a trial of electromotive transdermal delivery.
After prostatectomy: assisted erections versus spontaneous recovery
ICI can provide erections while nerve-dependent responses are poor. That symptomatic use should be distinguished from proof that scheduled injections restore unassisted erections sooner or more often.[2]
The Nauta 2025 rehabilitation cohort included 397 participants among 570 eligible men. Its reported recovery of up to 80% in selected combination-treatment groups included erections with treatment aids; groups differed in age and clinical characteristics. It does not validate one universal tadalafil/weekly-alprostadil/VED prescription or an 80% spontaneous-recovery promise.[8]
The Miranda randomized trial enrolled 76 men and had only 32 available across its three groups at 24 months. It found no significant final difference, but was too small/incomplete for a definitive negative conclusion. Cochrane's 2018 review mainly addressed scheduled PDE5 inhibitors and found very-low-certainty evidence; it did not establish that every multimodal injection program is effective or ineffective.[9][10]
See Also
- PDE5 inhibitors
- Intraurethral alprostadil
- Peyronie's disease agents
- Priapism management
- Testosterone replacement
- Peyronie's disease (clinical)
- Erectile dysfunction (clinical)
References
1. Burnett AL, et al. Erectile Dysfunction: AUA Guideline. 2018. Source.
2. EAU. Sexual and Reproductive Health Guideline, 2026. Management of erectile dysfunction. Source.
3. CAVERJECT (alprostadil). US prescribing information. Source.
4. EDEX (alprostadil). US prescribing information. Source.
5. Coombs PG, et al. Outcomes of an intracavernosal injection therapy programme. BJU Int. 2012. Source.
6. Al-Mitwalli A, et al. Aviptadil/phentolamine for refractory ED. J Sex Med. 2025. Source.
7. AUA/SMSNA. Diagnosis and Management of Priapism, 2022. Source.
8. Nauta MD, et al. Sexual function recovery following radical prostatectomy: academic rehabilitation program. Asian J Androl. 2025. Source.
9. Miranda EP, et al. Randomized three-arm pharmacological penile rehabilitation trial. J Sex Med. 2021. Source.
10. Philippou YA, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018;CD012414. Source.